Holen Sie sich die Stockscreener-App
34.29
49.34%
-33.40
Handel nachbörslich:
31.42
-2.87
-8.37%
Schlusskurs vom Vortag:
$67.69
Offen:
$23.05
24-Stunden-Volumen:
30.56M
Relative Volume:
8.46
Marktkapitalisierung:
$1.88B
Einnahmen:
$14.34M
Nettoeinkommen (Verlust:
$-199.00M
KGV:
-8.7474
EPS:
-3.92
Netto-Cashflow:
$-183.51M
1W Leistung:
-49.51%
1M Leistung:
-37.56%
6M Leistung:
+132.16%
1J Leistung:
+485.15%
1-Tages-Spanne:
$22.85
$36.19
1-Wochen-Bereich:
$22.85
$71.50
52-Wochen-Spanne:
$5.35
$71.50
Uniqure N V Stock (QURE) Company Profile
Firmenname
Uniqure N V
Sektor
Branche
Telefon
1-339-970-7000
Adresse
PAASHEUVELWEG 25A, AMSTERDAM
Vergleichen Sie QURE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
34.29 | 4.17B | 14.34M | -199.00M | -183.51M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-14 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-04-01 | Fortgesetzt | Chardan Capital Markets | Buy |
| 2024-12-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-02-29 | Herabstufung | Goldman | Buy → Neutral |
| 2023-12-19 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-17 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-21 | Eingeleitet | UBS | Neutral |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-01 | Hochstufung | Mizuho | Neutral → Buy |
| 2021-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-11-11 | Eingeleitet | Berenberg | Buy |
| 2020-11-09 | Eingeleitet | Jefferies | Buy |
| 2020-11-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-08-25 | Eingeleitet | Raymond James | Strong Buy |
| 2020-07-31 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-06-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Eingeleitet | Cowen | Outperform |
| 2019-12-03 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Eingeleitet | Credit Suisse | Outperform |
| 2019-10-11 | Eingeleitet | Stifel | Buy |
| 2019-09-25 | Eingeleitet | Bernstein | Outperform |
| 2019-09-12 | Eingeleitet | Mizuho | Buy |
| 2019-07-30 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-07-08 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-03-29 | Eingeleitet | Robert W. Baird | Outperform |
Alle ansehen
Uniqure N V Aktie (QURE) Neueste Nachrichten
PreBLA Meeting With FDA Sinks uniQure’s Hopes for Approval of Huntington Disease Gene Therapy AMT-130 Based on Phase 1/2 Data - CGTLive®
How FDA’s Revised Stance on AMT-130 Data Has Changed uniQure’s (QURE) Investment Story - simplywall.st
uniQure (QURE) Maintains Buy Rating as Chardan Capital Lowers Pr - GuruFocus
UniQure Reeling As FDA Reverses Stance On Accelerated Approval For AMT-130 - Citeline News & Insights
UniQure Shares Dive After ‘Surprising’ Pivot by FDA on Drug Data - Bloomberg.com
QURE Investor ALERT: Block & Leviton Investigating uniQure for Securities Fraud; Investors ... - Bluefield Daily Telegraph
QURE Investor ALERT: Block & Leviton Investigating uniQure - GlobeNewswire
INVESTOR ALERT: Investigation of uniQure N.V. (QURE) Announced by Holzer & Holzer, LLC - GlobeNewswire
Why UniQure Stock Is Plunging TodayuniQure (NASDAQ:QURE) - Benzinga
uniQure N.V. (QURE) Stock: Plunges 57% After Unexpected FDA Setback on AMT-130 - CoinCentral
QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with the Schall Law Firm - The AI Journal
uniQure (QURE) Shares Plunge Over 50% - GuruFocus
uniQure (QURE) Faces Setback with FDA on AMT-130 BLA Submission - GuruFocus
H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $110 - 富途牛牛
UniQure shares plummet as FDA says inadequate clinical data for Huntington's therapy - Reuters
UniQure stock crashes over 50% today after FDA says Huntington’s therapy data isn’t enoughhere's what i - The Economic Times
uniQure Stock Tumbled 55% Today: What’s The FDA Angle? - Stocktwits
uniQure (QURE) Price Targets Raised by Analysts After Positive Trial Results - MSN
uniQure stock falls after FDA feedback on gene therapy application - Seeking Alpha
uniQure (QURE) Faces FDA Reversal on AMT-130 Phase 1/2 Data - GuruFocus
Uniqure stock plunges after FDA rejects company’s clinical data for Huntington's therapy - Proactive financial news
uniQure (QURE) Shares Plummet Over 57% - GuruFocus
UniQure (QURE) Stock: Biotech Plunges 67% After FDA Reverses Position on Gene Therapy Data - parameter.io
UniQure Shares Fall Sharply as Trading Resumes After Volatility Halt - MarketScreener
uniQure N.V. Investigated for Securities Fraud ViolationsContact the DJS Law Group to Discuss Your Rights – QURE - The Globe and Mail
UniQure Stock Plummets 67% on Potential FDA Decision. Here's Why. -- Barrons.com - 富途牛牛
Top Premarket Decliners - 富途牛牛
How analysts rate uniQure N.V. stock today2025 Analyst Calls & Real-Time Buy Zone Alerts - newser.com
uniQure Shares Collapse 75% After FDA Reverses Position on Huntington’s Therapy - MSN
UniQure’s FDA submission for its Huntington’s disease therapy thrown into question - statnews.com
Predicting uniQure N.V. trend using moving averagesQuarterly Trade Review & Long-Term Growth Portfolio Plans - newser.com
UniQure Shares Fall Pre-Bell After FDA Raises Questions on Huntington's Disease Therapy Data - MarketScreener
uniQure (QURE) Faces Unexpected FDA Feedback on AMT-130 Gene The - GuruFocus
uniQure Faces FDA Setback on Huntington’s Therapy - TipRanks
Is uniQure N.V. stock trading at a premium valuationJuly 2025 Catalysts & Verified Momentum Stock Ideas - newser.com
FDA says clinical data for UniQure's Huntington's disease therapy not adequate - MarketScreener
uniQure N.V. Provides Regulatory Update on AMT-130 for Huntington's Disease - TradingView
uniQure stock plummets after FDA shifts stance on Huntington’s therapy By Investing.com - Investing.com South Africa
uniQure stock plummets after FDA shifts stance on Huntington’s therapy - Investing.com
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease - Yahoo Finance
uniQure N.V. stock outlook for YEARJuly 2025 Reactions & High Yield Stock Recommendations - newser.com
What data driven models say about uniQure N.V.’s future2025 Growth vs Value & High Accuracy Buy Signal Tips - newser.com
uniQure N.V. (NASDAQ:QURE) Short Interest Down 31.4% in October - MarketBeat
What catalysts could drive uniQure N.V. stock higherJuly 2025 PreEarnings & Capital Efficient Trade Techniques - newser.com
Can uniQure N.V. (UQ1) stock sustain revenue momentumWatch List & Stepwise Trade Signal Guides - newser.com
Can uniQure N.V. stock hit record highs againTrade Exit Summary & Free Safe Entry Trade Signal Reports - newser.com
Risk adjusted return profile for uniQure N.V. analyzedEarnings Overview Summary & Short-Term Swing Trade Alerts - newser.com
Can uniQure N.V. stock hit analyst price targetsTrade Risk Assessment & Long Hold Capital Preservation Plans - newser.com
Jennison Associates LLC Acquires Shares of 140,060 uniQure N.V. $QURE - MarketBeat
Finanzdaten der Uniqure N V-Aktie (QURE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):